Rosen Law Firm Invites ADMA Biologics Investors to Join Securities Fraud Lawsuit
ADMA Biologics investors who purchased securities between August 9, 2024, and March 25, 2026, have until August 10, 2026, to act as lead plaintiff in a securities fraud class action lawsuit filed by the firm.
Rosen Law Firm, a global investor rights law firm, is notifying purchasers of ADMA Biologics, Inc. (NASDAQ: ADMA) securities who bought between August 9, 2024, and March 25, 2026, inclusive, of an August 10, 2026 deadline. This date is important for investors wishing to serve as lead plaintiff in a securities class action lawsuit filed by the firm.
The lawsuit alleges that ADMA Biologics made materially false and misleading statements and failed to disclose key information during the class period. Specifically, the suit claims the company engaged in undisclosed related-party transactions, used channel stuffing to inflate revenue, and lacked adequate internal controls. When the true details emerged, investors are said to have suffered damages.
Rosen Law Firm encourages investors to select counsel with a proven track record in leadership roles, noting that many firms issuing such notices may not have comparable experience. The firm highlights its own concentration in securities class actions and shareholder derivative litigation, citing significant recoveries for investors.
Individuals who purchased ADMA Biologics securities during the specified period may be eligible for compensation without out-of-pocket costs through a contingency fee arrangement. The firm provides contact information for those seeking to learn more about the class action and the process for potentially serving as lead plaintiff.